Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MWX203 alone or with inclisiran in mixed dyslipidemia with inadequate lipid control
CTR20262397Phase 2Active
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Jun 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MWX203, inclisiran in combined dyslipidaemia, dyslipidemia, sponsored by Shanghai Minwei Biotechnology Co., Ltd.. Started Jun 2026; status: active.
02
Drugs
MWX203inclisiran
03
Conditions
combined dyslipidaemiadyslipidemia
Beyond the preview
Go deeper on CTR20262397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262397.